Esophageal Cancer
Esophageal cancer in brief
Esophageal cancer accounts for about 1 % of all cancers; in Germany, around 7,500 people develop it each year. This makes it one of the less common cancers. Men develop it about three times as often as women. The median age at diagnosis is about 70. Esophageal cancer is often discovered only at a late stage.
Esophageal cancer at a glance
- Frequency
- About 1 % of all cancers
- New cases in Germany
- Around 7,500 per year
- Typical age
- Median age at diagnosis about 70
- Sex
- Men develop it about three times as often as women
What exactly is esophageal cancer?
There are two subtypes of esophageal cancer. Squamous cell carcinoma arises from the cells that line the inside of the esophagus and can occur in any part of it. Adenocarcinoma arises from glandular cells, usually in the lower part where the esophagus joins the stomach – often on the basis of a lining that has been changed by years of acid reflux (Barrett's esophagus). The two forms differ in their risk factors and partly also in their treatment; more on this below.
Why do I have esophageal cancer?
There is no single cause of esophageal cancer, but some risk factors are known. For squamous cell carcinoma, smoking and alcohol consumption are the main factors, while adenocarcinomas are linked to reflux and excess weight. Risk factors include:
Squamous cell carcinoma:
- Smoking and alcohol, depending on the amount – together they reinforce each other
- Male sex
- Radiation to the neck or chest area
- Achalasia, a rare functional disorder of the esophagus
Adenocarcinoma:
- Reflux: stomach acid flows back into the esophagus and can change its lining over time (Barrett's esophagus)
- Excess weight
- Smoking
- Male sex
It is important to say that esophageal cancer does not necessarily occur as soon as one or more of these risk factors are present. There are, however, recommendations for preventing esophageal cancer: avoiding excessive alcohol consumption, not smoking, a diet rich in fruit and vegetables, and treating persistent heartburn.
Symptoms of esophageal cancer
Esophageal cancer is often discovered only at late stages. One reason for this is that symptoms often appear only once the tumor noticeably narrows the inside of the esophagus. Symptoms include:
- Problems or pain when swallowing, first with solid food, later also with soft food
- Recurrent vomiting and nausea
- Little or no appetite
- Feeling full early
- Weight loss
- Pain behind the breastbone, hoarseness, or a persistent cough
- Bleeding in the gastrointestinal tract: it can show up, for example, as very dark stool or as anemia
When is esophageal cancer treated?
The diagnosis is confirmed by an endoscopy, that is, an examination of the esophagus with a camera, during which tissue samples are taken. Further tests (computed tomography, endoscopic ultrasound, and PET/CT if needed) are then used to determine the stage. As a rule, treatment is started promptly. It differs depending on the subtype, the stage, the location of the tumor, and whether a person is fit enough for surgery.
How is esophageal cancer treated?
The best treatment is decided in a multidisciplinary tumor board. Options may include:
- Endoscopic resection (removal): the cancer is cut out locally during the endoscopy; this is only an option at very early stages of cancer.
- Surgical resection: part or all of the esophagus is removed and replaced by a tube made from the stomach that is pulled up, or by a section of intestine – a major operation that should be performed at specialized centers.
- Preoperative therapy: treatment before surgery, depending on the subtype with chemoradiotherapy or chemotherapy (for adenocarcinoma usually FLOT, see stomach cancer)
- Postoperative therapy: treatment after surgery, e.g. with chemotherapy or immunotherapy
- Chemoradiotherapy: radiation and chemotherapy combined – before surgery or as the only treatment if surgery is not possible or not wanted (especially for squamous cell carcinoma)
- Immunotherapy: drugs that help the immune system fight the cancer – after surgery or at advanced stages
How exactly have clinical trials changed the treatment landscape for esophageal cancer?
Clinical trials have contributed substantially to improving the treatment of esophageal cancer. In particular, surgery is now complemented by treatments before and after the operation. In addition, treatment is tailored to the subtype and the stage. One example is the
- CROSS trial: This Dutch trial enrolled 368 patients who either had surgery right away or received radiation with weekly chemotherapy before surgery. The trial showed that chemoradiotherapy before surgery clearly prolongs survival – even after ten years, more patients were still alive. It is now part of the treatment recommendations for squamous cell carcinoma and – alongside perioperative chemotherapy (FLOT) – also for adenocarcinoma.
Another trial is
- CheckMate 577: This international trial enrolled 794 patients in whom residual tumor had still been found in the removed tissue after chemoradiotherapy and surgery. They were divided into two groups: one group received immunotherapy with nivolumab for one year, the other a dummy drug (placebo). With immunotherapy, the time without relapse doubled (a median of 22 instead of 11 months). This treatment has been the standard for this group of patients ever since.
These examples show how recommendations change on the basis of clinical trials. Interested in taking part in clinical trials? Then take a look here at the current trials in Germany.
This information is not a substitute for a conversation with your doctor.
Last updated:
Sources (3)
- Onkopedia-Leitlinie · Ösophaguskarzinom (opens in a new tab)
- Eyck BM et al.: Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial · J Clin Oncol 2021 (opens in a new tab)CROSS
- Kelly RJ et al.: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer · N Engl J Med 2021 (opens in a new tab)CheckMate 577